1. 3rd Annual Vaccine
Manufacturing
Identifying strategies for better manufacturing and development
18th – 19th April 2011, London, UK BOOK NOW!
Key Speakers
Abbas Rashidbaigi, Director, Pfizer
Alastair Leighton, Head of New Primary Operations, Novartis
Simon Hsu, Associate Director, MedImmune
Elizabeth Pollitt, Quality Assessor, Medicines and Healthcare products Regulatory Agency (MHRA)
Farzin Farzaneh, Professor of Molecular Medicine, King’s College London
Herman van Herk, Scientist Up Stream Process Development, Crucell
Ruth Harvey, Scientist, the National Institute for Biological Standards and Control (NIBSC)
Dennis Christensen, Head of Section Vaccine Delivery and Formulation, STATENS SERUM INSTITUT (SSI)
Alistair Noble, Senior Lecturer, King’s College London
Nigel Allison, Process Development Specialist, Health Protection Agency
Driving the Industry Forward | www.futurepharmaus.com
Media Partners Organised By
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/vaccinemanufacturing

2. Conference Introduction
3rd Annual Vaccine Manufacturing
18th - 19th April 2011, London, UK
Dear Colleague, Media Partners:
he global vaccine market will achieve sustained growth over the next 15 years,
T PharmiWeb.com is the leading industry-sponsored portal
and this trend is likely to continue as governments recognise the importance for the pharmaceutical sector. Supported by most of
of mass vaccination (Source: Visiongain Report ‘Global Vaccines Market, 2010- the leading pharmaceutical corporations, PharmiWeb.com provides dynamic
2025’ published: March 2010) real-time news, features, events listings and international jobs to industry
professionals across Europe and the US.
he growth in the vaccine market as well as recent outbreaks in avian and
T For further information please email: corporate@pharmiweb.com
swine flu has highlighted the need for innovation in the manufacturing and
development of vaccines to bring greater efficiencies.
isiongain’s 3rd Annual Vaccine Manufacturing conference will feature key
V BIOTECHNOLOGY EUROPE is owned by
industry experts, who will assess the current landscape of vaccine development BIOTECHNOLOGY WORLD. It is based and located in
and address challenges face by manufactures. The attendees will hear the latest Warsaw, Poland. Biotechnology World was founded in 2007 to provide the
innovative strategies and technologies. Join us and be inspired. world’s biotech and pharma information and market to make it universally
accessible and useful for scientific and business processes. Its first step
Why you should attend this conference to fulfilling that mission was building the BIOTECHNOLOGY EUROPE
• Identify innovative vaccine developments and manufacturing strategies platform that will allow a quick spread of information in different channels.
BIOTECHNOLOGY EUROPE offers companies completed internet public
• Review important regulatory requirements relations, publication and marketing solutions. One of the mains goals of
• Assess immunological challenges BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in
Europe to global biotechnology, pharmaceutical and life science activities.
• Understand strategies for improving influenza vaccine strains For further information please visit: www.biotechnology-europe.com
• Explore opportunities in emerging markets
• Use this platform to forge future business collaborations Future Pharmaceuticals has forged powerful
Driving the Industry Forward | www.futurepharmaus.com
relationships with key industry leaders to provide a
I look forward to meeting you at the conference
platform for successful brand recognition, and for senior decision-makers to
Best regards have the means to procure and plan implementation strategies based on the
topics covered. Positioned to be an authoritative resource within top pharma
companies as well as small, specialty, and biotech, Future Pharmaceuticals
magazine is geared to create a deep penetration into a highly targeted and
responsive audience, bridging the gap between the industries’ top issues and
Koos Mohammed the solutions top-tier vendors can provide.
Conference Producer For further information please visit: www.futurepharmaus.com
InPharm is the online platform for exclusive
pharmaceutical news, comment, contracts, services, jobs
and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus.
Who should attend this conference?
For further information please visit: www.In-Pharm.com
VPs, Directors, Heads, Managers working within:
Vaccine equipment and manufacturing
Vaccine application development
Vaccinology and molecular biology
Sponsorship and exhibition opportunities
Proteomics, recombinant protein/DNA biotechnology
Infectious disease R&D This event offers a unique opportunity to meet and do business with some
Pharmacovigilance and safety testing of the key players in the pharmaceutical and biotech industries. If you have
Regulatory affairs a service or product to promote, you can do so at this event by:
Strategic product development
• Hosting a networking drinks reception
Manufacturing/production
• Taking an exhibition space at the conference
Chemistry manufacturing and controls
• Advertising in the delegate documentation pack
Process control and Analytical Technologies
Clinical product resourcing • Providing branded bags, pens, gifts, etc.
Supply outsourcing project management If you would like more information on the range of sponsorship or
Contract management exhibition possibilities for visiongain's 3rd Annual Vaccine Manufacturing
Process development
Conference, please contact us:
Drug discovery & deliver
Legal Affairs Ronald Magali, +44 (0)20 7549 9934
Investment and venture capital ronald.magali@visiongainglobal.com

3. Day 1
3rd Annual Vaccine Manufacturing
Monday 18th April 2011
09:00 Registration and refreshments 12:40 Networking lunch
09:30 Opening address from the chair 13:40 Presentation to be announced
Alastair Leighton
Head of New Primary Operations
09:40 Regulatory requirements for vaccines Novartis
• uality requirements for marketing authorisation of a new vaccine
Q
• ost licensing issues arising from manufacturing changes
P
14:20 Abrogating CD8 T cell tolerance with
• istorical examples to high light problems
H multifactorial adjuvants
• uccessful strategies to implement manufacturing changes
S • Nature of CD8 T cell tolerance
Elizabeth Pollitt • Pathways leading to clonal expansion of Ag-specific CD8 T cells
Quality Assessor
• omponents of multifactorial adjuvants required for CTL responses
C
MHRA
and tumour rejection
Alistair Noble
Senior Lecturer
10:20 The redevelopment of licensed vaccines
King’s College London
• Why redevelop a mature process?
• The regulatory challenges
15:00 Afternoon Refreshments
• Process redevelopment
• Application of improved analytical methods
• Anthrax vaccine: A case study 15:20 Increasing access to pandemic influenza vaccines
Nigel Allison • Sustaining appropriate manufacturing capacity
Process Development Specialist
• Enhancing vaccine performance
Health Protection Agency
• Process improvements
Simon Hsu
11:00 Morning refreshments Associate Director
MedImmune
11:20 Tailoring adjuvants for future vaccines
16:00 The case for cell-based manufacturing methods
• Challenges in vaccinology
• Faster vaccine production
• Accessible vs. ideal adjuvants
• Ideal in times of pandemic
• Administration route and immunity
• Reduced allergic reactions
Dennis Christensen
Head of Section, Vaccine Delivery and Formulation
Statens Serum Institut
16:40 Closing remarks from the chair
12:00 Immunological challenges in developing
vaccines for malaria
• Antigenic variation and polymorphism 16:50 Networking drinks
• Immunological non-responsiveness to individual vaccine antigens Take your discussions further and build new
• Parasite-induced apoptosis of immune effector and memory cells relationships in a relaxed and informal setting
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011

4. Day 2
3rd Annual Vaccine Manufacturing
Tuesday 19th April 2011
09:00 Registration and refreshments 12:40 Networking lunch
09:30 Opening address from the chair 13:40 Outsourcing vaccine production
• Developing an outsourcing strategy
• Accessing appropriate equipment
09:40 Cell, gene and peptide based vaccines for
therapeutic applications in cancer • Coping with the demand during pandemics
• Immune mediated rejection of established tumours
• afety and potential efficacy of hTERT peptide loaded dendritic
S
14:20 Improving influenza vaccine strains
cell vaccination
• Generation of candidate vaccine viruses
• ew vaccination strategy based on the combined adjuvants for
N
synergistic activation of cellular immunity (CASAC) • Genetic engineering of vaccine strains
Farzin Farzaneh • Improved antigen yield from new candidate vaccine viruses
Professor of Molecular Medicine
Ruth Harvey
King’s College London
Scientist
National Institute for Biological
Standards and Control (NIBSC)
10:20 Thimerosal in Vaccines: Is it an
effective preservative?
• ompendial methods for determination of preservative effectiveness
C 15:00 Afternoon refreshments
• HO requirements
W
• reservatives for multi-dose formulations
P 15:20 Post-license safety monitoring
• election of a preservative for Prev(e)nar 13™ vaccine
S • Use of data to evaluate emerging safety issues
• low rate of Thimerosal effectiveness
S • Evaluation of post-marketing adverse event reports
Abbas Rashidbaigi
Director
Pfizer
16:00 Emerging vaccine markets
• Strengths and weaknesses
11:00 Morning refreshments • Challenges and opportunities
16:40 Chair’s closing remarks
11:20 Sponsor Spotlight Session
T
ake this unique opportunity to be a part of the conference theme,
network, share ideas and provide an overview of your product/services 16:50 End of Conference
to the audience. For more information please contact
ronald.magali@visiongainglobal.com
12:00 Novel technologies for improving the scale of
production of influenza vaccine
• Speeding up the production process
• Fewer contamination
Herman van Herk
Scientist Up Stream Process Development
Crucell

5. Registration Form
3rd Annual Vaccine Manufacturing
18th - 19th April 2011, London, UK
Conf. code VG
Standard Prices
3rd Annual Vaccine Manufacturing
Conference only Fee: £1299 VAT: £259.80 Total: £1558.80
18th - 19th April 2011
Number of bookings: Total cost:
London, UK
Promotional Literature Distribution
Distribution of your company’s promotional literature to all conference attendees
Fee: £999 VAT: £199.80 Total: £1198.80
Details
How to book
Forename: Surname: Email: conferences@visiongainglobal.com
Web: http://www.visiongain.com/vaccinemanufacturing
Job Title: Company: UK Office:
Tel: +44(0) 20 7336 6100
Main Switchboard Number: Fax: +44(0) 20 7549 9932
Visiongain Ltd
Address: BSG House
226-236 City Road
London
EC1V 2QY
UK
Country: Postcode:
General information
Venue: TBA, London, UK
Phone: Fax:
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
Email: be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
right to charge interest on unpaid invoices.
Signature: Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
I confirm that I have read and agree to the terms and conditions of booking after one month before the start of the event. Should you decide to cancel after this date, the full invoice
must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
between conferences. However, if you cannot attend the conference, you may make a substitution/name
Methods of payment change at any time, as long as we are informed in writing by email, fax or post. Name changes and
Payment must be made in sterling substitutions must be from the same company or organisation and are not transferable between
countries. Please note that discounted delegates places at a visiongain event are non refundable.
By Mail: Complete and return your signed registration form together with your cheque payable Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK excluding substitutions/name changes, requested by the customer. This will be charged to the
customer by credit card prior to the changes being made.
By Fax: Complete and fax your signed registration form with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
to +44 (0) 20 7549 9932 briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
expenses, which may be incurred by the customer as a consequence of the event being postponed or
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
cost of the registration, travel and expenses.
By Bank Transfer:
Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
Visiongain Ltd A/C: visiongain Ltd Protection Act 1988. Your personal information contained in this form may be used to update you on
Barclays Bank Sort Code: 20-71-64 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
may also share your data with external companies offering complementary products or services. If you
Piccadilly Branch Account No: 6038 7118 wish for your details to be amended, suppressed or not passed on to any external third party, please
48 Regent Street Swift Code: BARC GB22
send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
London, W1B 5RA IBAN: GB80 BARC 20716460387118 Please allow approximately 30 days for your removal or update request to be applied to our database.
Please debit my credit card: Following your removal or update request, you may receive additional pieces of communication from
visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Access MasterCard Visa American Express Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
recommend you obtain).
Card number: VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Eurocash specialise in recovering cross-border VAT.
Expiry Date: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Security number (last 3 digits on back of credit card): Unable to attend
Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
Signature: with your payment. You will receive speaker talks in PDFs two weeks after the event.
Yes, please send me speaker talks Price£550 VAT:£110 Total:£660
Cardholder’s name:
Office use only
News updates
Please tick if you do not want to receive email news updates in the future
www.visiongain.com/vaccinemanufacturing